138 related articles for article (PubMed ID: 8580391)
21. Fluoxetine in the prevention of depressive recurrences: a double-blind study.
Gilaberte I; Montejo AL; de la Gandara J; Perez-Sola V; Bernardo M; Massana J; Martin-Santos R; Santiso A; Noguera R; Casais L; Perez-Camo V; Arias M; Judge R;
J Clin Psychopharmacol; 2001 Aug; 21(4):417-24. PubMed ID: 11476126
[TBL] [Abstract][Full Text] [Related]
22. The effect of fluoxetine on anxiety and depression symptoms in cancer patients.
Razavi D; Allilaire JF; Smith M; Salimpour A; Verra M; Desclaux B; Saltel P; Piollet I; Gauvain-Piquard A; Trichard C; Cordier B; Fresco R; Guillibert E; Sechter D; Orth JP; Bouhassira M; Mesters P; Blin P
Acta Psychiatr Scand; 1996 Sep; 94(3):205-10. PubMed ID: 8891089
[TBL] [Abstract][Full Text] [Related]
23. Predictors of response to amine-specific antidepressants.
Burns RA; Lock T; Edwards DR; Katona CL; Harrison DA; Robertson MM; Nairac B; Abou-Saleh MT
J Affect Disord; 1995 Dec; 35(3):97-106. PubMed ID: 8749837
[TBL] [Abstract][Full Text] [Related]
24. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder.
Fava M; McCall WV; Krystal A; Wessel T; Rubens R; Caron J; Amato D; Roth T
Biol Psychiatry; 2006 Jun; 59(11):1052-60. PubMed ID: 16581036
[TBL] [Abstract][Full Text] [Related]
25. Placebo-controlled treatment trial of depression in elderly physically ill patients.
Evans M; Hammond M; Wilson K; Lye M; Copeland J
Int J Geriatr Psychiatry; 1997 Aug; 12(8):817-24. PubMed ID: 9283926
[TBL] [Abstract][Full Text] [Related]
26. Are neurovegetative symptoms stable in relapsing or recurrent atypical depressive episodes?
Nierenberg AA; Pava JA; Clancy K; Rosenbaum JF; Fava M
Biol Psychiatry; 1996 Oct; 40(8):691-6. PubMed ID: 8894060
[TBL] [Abstract][Full Text] [Related]
27. The relationship between early changes in the HAMD-17 anxiety/somatization factor items and treatment outcome among depressed outpatients.
Farabaugh A; Mischoulon D; Fava M; Wu SL; Mascarini A; Tossani E; Alpert JE
Int Clin Psychopharmacol; 2005 Mar; 20(2):87-91. PubMed ID: 15729083
[TBL] [Abstract][Full Text] [Related]
28. A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression.
Rudolph RL; Feiger AD
J Affect Disord; 1999 Dec; 56(2-3):171-81. PubMed ID: 10701474
[TBL] [Abstract][Full Text] [Related]
29. Course of psychomotor agitation during pharmacotherapy of depression: analysis from double-blind controlled trials with fluoxetine.
Tollefson GD; Sayler ME
Depress Anxiety; 1996-1997; 4(6):294-311. PubMed ID: 9166658
[TBL] [Abstract][Full Text] [Related]
30. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group.
Clerc GE; Ruimy P; Verdeau-Pallès J
Int Clin Psychopharmacol; 1994 Sep; 9(3):139-43. PubMed ID: 7814822
[TBL] [Abstract][Full Text] [Related]
31. Early fluoxetine treatment of post-stroke depression--a three-month double-blind placebo-controlled study with an open-label long-term follow up.
Fruehwald S; Gatterbauer E; Rehak P; Baumhackl U
J Neurol; 2003 Mar; 250(3):347-51. PubMed ID: 12638027
[TBL] [Abstract][Full Text] [Related]
32. A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients.
Nemeroff CB; Thase ME;
J Psychiatr Res; 2007; 41(3-4):351-9. PubMed ID: 16165158
[TBL] [Abstract][Full Text] [Related]
33. Prediction of response to fluoxetine and placebo in children and adolescents with major depression: a hypothesis generating study.
Kowatch RA; Carmody TJ; Emslie GJ; Rintelmann JW; Hughes CW; Rush AJ
J Affect Disord; 1999 Aug; 54(3):269-76. PubMed ID: 10467970
[TBL] [Abstract][Full Text] [Related]
34. A double-blind study of paroxetine compared with fluoxetine in geriatric patients with major depression.
Schöne W; Ludwig M
J Clin Psychopharmacol; 1993 Dec; 13(6 Suppl 2):34S-39S. PubMed ID: 8106654
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness of fluoxetine therapy in bulimia nervosa regardless of comorbid depression.
Goldstein DJ; Wilson MG; Ascroft RC; al-Banna M
Int J Eat Disord; 1999 Jan; 25(1):19-27. PubMed ID: 9924649
[TBL] [Abstract][Full Text] [Related]
36. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder.
Garakani A; Martinez JM; Marcus S; Weaver J; Rickels K; Fava M; Hirschowitz J
Int Clin Psychopharmacol; 2008 Sep; 23(5):269-75. PubMed ID: 18703936
[TBL] [Abstract][Full Text] [Related]
37. Is metabolic dysregulation associated with antidepressant response in depressed women in climacteric treated with individualized homeopathic medicines or fluoxetine? The HOMDEP-MENOP Study.
Macías-Cortés ED; Llanes-González L; Aguilar-Faisal L; Asbun-Bojalil J
Homeopathy; 2017 Feb; 106(1):3-10. PubMed ID: 28325221
[TBL] [Abstract][Full Text] [Related]
38. Estrogen replacement and response to fluoxetine in a multicenter geriatric depression trial. Fluoxetine Collaborative Study Group.
Schneider LS; Small GW; Hamilton SH; Bystritsky A; Nemeroff CB; Meyers BS
Am J Geriatr Psychiatry; 1997; 5(2):97-106. PubMed ID: 9106373
[TBL] [Abstract][Full Text] [Related]
39. Fluoxetine versus amitriptyline in the treatment of major depression with associated anxiety (anxious depression): a double-blind comparison.
Versiani M; Ontiveros A; Mazzotti G; Ospina J; Dávila J; Mata S; Pacheco A; Plewes J; Tamura R; Palacios M
Int Clin Psychopharmacol; 1999 Nov; 14(6):321-7. PubMed ID: 10565798
[TBL] [Abstract][Full Text] [Related]
40. Hopelessness as a predictor of non-response to fluoxetine in major depressive disorder.
Papakostas GI; Petersen T; Homberger CH; Green CH; Smith J; Alpert JE; Fava M
Ann Clin Psychiatry; 2007; 19(1):5-8. PubMed ID: 17453655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
